Effectiveness of the use of DAFS-25 in the Standard Hepatitis Treatment Regimen for Dogs
The article provides a study on the effectiveness of the drug DAFS-25 in the standard hepatitis treatment regimen for dogs. The study was conducted in a veterinary clinic «Alabai», Astrakhan, based on the treatment of dogs of the Caucasian wolfhound breed from Kangly kennel. Key indicators of liver status in dogs were taken in the study: alkaline phosphatase (ALP), ALT, AST, ALB (albumin), (TB) total bilirubin, (TР) total protein; in the process of treatment, based on the results of the biochemical rapid analyzer Seamaty 120VP, animals were divided into three groups (one control and two experimental groups) by analyzing their state. Fifteen dogs aged 3-6 were reviewed in the study, the average weight of animals was 65 kg. Biochemical analysis was carried out at the beginning of the study, on the twentieth day and after the end of therapy. The standard treatment regimen was used in the control group and the drug DAFS-25 was added into the standard treatment regimen of experimental groups at a dose of 1.6 mg/kg (104 mg/head) in the second group and 4.8 mg/kg (312 mg/head) in the third group. There were no lethal outcomes during the study period. The drug DAFS-25 was taken for the research, as it has strong antioxidant properties, positively affects the animals’ body from negative environmental factors, fills selenium deficiency in the body of animals. It positively affects the composition of the blood, improves metabolic processes of the whole organism. As a result of treatment, the general condition of the animals who received therapy came to the physiological norm, biochemical parameters taken at the end of therapy returned to normal, which indicated a complete recovery of the dogs. Studies have shown the efficacy of the drug in the second and third experimental groups, which allows to suggest the drug DAFS-25 as an alternative to other hepatoprotective drugs in the treatment of liver diseases and hepatitis.
